Home/Pipeline/SEI-117

SEI-117

Allergic Conjunctivitis

Phase 3Active

Key Facts

Indication
Allergic Conjunctivitis
Phase
Phase 3
Status
Active
Company

About Santen Pharmaceutical

Santen's mission is to contribute to the well-being of patients, society, and employees by addressing ophthalmic diseases through specialized innovation. The company has achieved a leading global position in ophthalmology with a robust commercial portfolio and a deep R&D pipeline focused on glaucoma, retinal diseases, and ocular surface disorders. Its strategy is built on a vertically integrated, ophthalmology-focused model that enables deep expertise, operational efficiency, and targeted global expansion in both developed and emerging markets.

View full company profile

Therapeutic Areas

Other Allergic Conjunctivitis Drugs

DrugCompanyPhase
TearScan IgEAxim BiotechApproved
ReproxalapAldeyra TherapeuticsPhase 3